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Objective: To evaluate renal impairment in type 2 diabetic patients with normoalbuminuria
or  microalbuminuria by detection of serum cystatin C and serum and urinary TGF- levels.
Methods: Cross-sectional study conducted at the Department of Endocrinology in Baskent
University School of Medicine. Patients with type 2 diabetes mellitus without known overt
diabetic nephropathy were included in the study. Recruited patients were stratiﬁed into
four groups, matched in terms of age, gender, microalbuminuria level and estimated GFR
calculated with MDRD.
Results: 78 patients were enrolled. They were categorized into four groups depending on
their urinary albumin excretion and estimated glomerular ﬁltration rate.
Macrovascular complication was found to be higher in patients with microalbuminuria
than in other patients (p < 0.01), but there were no differences in terms of other diabetic
complications. Serum cystatin C level was signiﬁcantly higher in normoalbuminuric group
one  patients, while serum and urinary TGF-1 levels were higher in microalbuminuric group
two patients. The serum level of cystatin C was found to negatively correlate with eGFR in
group two patients (r = −0.892, p < 0.001). Finally, there was a negative correlation between
eGFR and cystatin C in all the patient groups (r = −0.726, p = 0.001).
Conclusions: Although urinary albumin excretion is recommended for the detection of type
two  diabetic nephropathy, there is a group of patients with decreased eGFR but without
increased urinary albumin excretion, in which serum cystatin C level was indicated to be
used  as an early biomarker of diabetic nephropathy.©  2016 Published by Elsevier Espan˜a, S.L.U. on behalf of Sociedad Espan˜ola de Nefrologı´a.
This  is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).∗ Corresponding author.
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ttp://dx.doi.org/10.1016/j.nefro.2016.06.011
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Concentración  de  cistatina  C  y  TGF- en  pacientes  con  nefropatía
diabética
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r  e  s  u  m  e  n
Objetivo: Evaluar la insuﬁciencia renal en pacientes con diabetes tipo 2 con normoalbumin-
uria  o microalbuminuria mediante la detección de la concentración de cistatina C en suero
y  de TGF- en suero y orina.
Métodos: Estudio transversal realizado en el Departamento de Endocrinología de la Facultad
de Medicina de la Universidad de Baskent. En el estudio, se incluyó a pacientes con diabetes
mellitus tipo 2 sin nefropatía diabética maniﬁesta conocida. Los pacientes seleccionados se
estratiﬁcaron en 4 grupos, agrupados en términos de edad, sexo, grado de microalbuminuria
y  ﬁltración glomerular estimada (FGe) calculada mediante la fórmula MDRD.
Resultados: Se incluyó a 78 pacientes. Se clasiﬁcaron en 4 grupos dependiendo de la excreción
urinaria de albúmina y de la FGe.
Se observó que la complicación macrovascular era mayor en los pacientes con microalbu-
minuria que en otros (p < 0,01), pero no hubo diferencias con relación a otras complicaciones
diabéticas. La concentración sérica de cistatina C fue signiﬁcativamente mayor en los
pacientes del grupo 1 con normoalbuminuria, mientras que las concentraciones de TGF-1
en  suero y orina fueron mayores en los pacientes del grupo 2 con microalbuminuria. Se
observó una correlación negativa entre la concentración sérica de cistatina C y la FGe en los
pacientes del grupo 2 (r = −0,892, p < 0,001). Por último, se observó una correlación negativa
entre la FGe y la cistatina C en todos los grupos de pacientes (r = −0,726, p = 0,001).
Conclusiones: Aunque se recomienda la excreción urinaria de albúmina para la detección
de la nefropatía diabética tipo 2, hay un grupo de pacientes con disminución de la FGe,
pero sin aumento de la excreción urinaria de albúmina, en los que estaba indicado usar
la  concentración de cistatina C en suero como un biomarcador temprano de nefropatía
diabética.
©  2016 Publicado por Elsevier Espan˜a, S.L.U. en nombre de Sociedad Espan˜ola de
Nefrologı´a.  Este es un artı´culo Open Access bajo la licencia CC BY-NC-ND (http://
nary system ultrasonography, urine microscopy and urineIntroduction
Diabetic nephropathy (DN) is the leading cause of chronic
kidney disease.1,2 Albumin excretion rate (AER) and glomeru-
lar ﬁltration rate (GFR) are used to stage DN. However, these
measurements are not sufﬁcient in early diagnosis and mon-
itoring the progression of DN. Therefore early markers should
be devised for these purposes. Although microalbuminuria
is accepted as a risk factor and marker for DN and pro-
gressive renal insufﬁciency,3 some patients, especially type 2
diabetics, may have normoalbuminuric chronic kidney
disease.4
This shows that both normoalbuminuric and albuminuric
pathways are at work.5 While some patients with MA present
with normal kidney structure, some other normoalbuminuric
diabetics have well-determined nephropathic lesion.6,7
Cystatin C which is used for measurement of GFR, is
produced in all nucleated cells and ﬁltered freely from the
glomerulus. It is reabsorbed totally and catabolised in the
proximal tubules. Cystatin C is a suitable marker for GFR mea-
surement owing to not being affected by age, weight, gender
and protein intake.8–10
Transforming growth factor-beta (TGF-1)  is one of the
growth factors which are implicated in DN pathogenesis.
TGF-1 causes mesangial extension by promoting renal cel-
lular hypertrophy and by inducing the extracellular matrixcreativecommons.org/licenses/by-nc-nd/4.0/).
expansion.11 Urinary TGF-1 levels are increased as propor-
tional to the severity of the nephropathy.12
We  aimed to determine the value of serum Cystatin C and
TGF-1 in early detection of diabetic nephropathy in normoal-
buminuric patients with type-2 diabetes mellitus.
Material  and  methods
Patients
This was a cross-sectional study which was conducted at the
Department of Endocrinology in Baskent University School
of Medicine, Istanbul, Turkey, during 2009–2011, who  agreed
to participate in the study. Baskent University Ethical Com-
mittee approved the study protocol (Approval no: KA09/308).
Patients with type 2 diabetes mellitus without known overt
diabetic nephropathy were included in the study. Recruited
patients were stratiﬁed into four groups, matched in terms of
age, gender, microalbuminuria level and estimated GFR cal-
culated with MDRD. We tried to exclude apparent causes of
nondiabetic renal disease based on data obtained with uri-culture. Patients who have history of nondiabetic renal dis-
ease, uncontrolled hypertension, liver disease, NYHA stage
3–4 heart failure, thyroid disease, malignity and steroid usage
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Fig. 1 – Correlation of serum cystatin C with eGFR in all fourn e f r o l o g i a 2 0 1
ere excluded from the study. All participants were included
n the study after signing informed consent forms.
aboratory  evaluation
ollowing thorough medical history and detailed physical
xamination, blood samples were taken from all participants
or measurement of fasting blood glucose, HbA1c, blood urea,
reatinine and electrolytes, lipid proﬁle, serum albumin, high
ensitive C reactive protein (hsCRP). Freshly voided early
orning urine samples were also collected for urinalysis.
atients also provided 24-h collected urine specimens for mea-
urement of microalbumin.
Serum glucose, creatinine, total cholesterol, HDL and LDL
holesterol, triglyceride were studied by enzymatic colori-
etric; serum albumin; bromocresol green (BCG), ure; (BUN)
rease, HbA1c; immune-examination (C4000, Abbott, USA),
nd hsCRP was studied with immunoturbidimetric methods
C8000, Abbott, USA). Microalbumin level in 24-h urine was
etermined with immunoturbidimetric method (C4000 sys-
em, Abbott, USA).
Estimated GFR was calculated with 6 variable MDRD equa-
ion using age, race, gender, serum creatinine, blood urea
itrogen and albumin values.13
The serums of patients were stored in −20 ◦C until lab-
ratory analysis. Serum cystathionine C, serum TGF-1 and
rine TGF-1 levels were determined with enzyme linked
mmunosorbent assay (ELISA) method. BioVendor (Czech
epublic) ELISA kit and eBioscience (North America) ELISA
ere used for Cystatin C and TGF-1 measurements, respec-
ively.
tatistical  analysis
or statistical evaluation, NCSS (Number Cruncher Statisti-
al System) 2007 and PASS (Power Analysis and Sample Size)
008 Statistical Software (Utah, USA) programs were used.
neway Anova test was used in intergroup comparison of
he parameters showing normal distribution and Tukey HDS
est was used in the determination of the group causing the
ifference. Kruskal–Wallis test was used in intergroup com-
arison of the parameters not showing normal distribution
nd Mann–Whitney U test was used in the group causing the
ifference. In comparison of the qualitative data, Chi-square
est was used. The signiﬁcance was accepted as p < 0.05.
esults
 total of 78 patients with type 2 DM were included in the
tudy (mean age 57 ± 8. Four groups were described; patients
ith GFR value <60 ml/min/1.73 m2 and MA <30 mg/day as
roup 1; patients with GFR value <60 ml/min/1.73 m2 and MA
etween 30 mg  and 300 mg/day as group 2; patients with GFR
alue >120 ml/min/1.73 m2 and MA  <30 mg/day as group 3, and
atients with GFR value between 90 and 120 ml/min/1.73 m2nd MA  <30 mg/day as group 4. There were 10 men  and 10
omen in group 1 and 4 whereas 10 men  and 11 women in
roup 2 and 15 men  and 2 women in group 3. The laboratory
arameters of the groups are shown in Table 1. Signiﬁcantstudy groups.
difference was present among groups with regards to mean
age, fasting blood glucose, HbA1c and serum creatinine level.
No signiﬁcant difference was found among groups in terms
of the presence of HT which has a major role in DN  patho-
genesis. The evaluation of the groups in terms of micro and
macrovascular complications of diabetes is depicted in Table 2.
Highest rate of coronary artery disease (CAD) was seen Groups
1 and 2. No signiﬁcance difference was evident among the
groups regarding prevalence of retinopathy, diabetic foot and
neuropathy (p > 0.05).
Results of GFR, cystatin C, serum and urine TGF-1, MA
measurements are shown in Table 3. Signiﬁcant difference
was present among the groups in terms of cystatin C, serum
and urine TGF-1 (p < 0.05). Post Hoc Tukey HSD test which was
performed to determine the intragroup signiﬁcance, showed
that cystatin C level of groups 1 and 2 was signiﬁcantly higher
compared with those of groups 3 and 4 (for Group 1; p = 0.001,
p = 0.001; for Group 2; p = 0.002, p = 0.01). For the serum and
urine TGF-1, we found that the levels in group 2 were signif-
icantly higher than group 4 (p = 0.012; p = 0.012). No signiﬁcant
association was determined between TGF-1 and any of the
studied variables.
Cystatin C showed a signiﬁcant and positive correlation
with age, duration of diabetes, and serum uric acid in group
2 (for age: r = 0.477, p = 0.029; for duration of diabetes: r = 0.437,
p = 0.048; for serum uric acid: r = 0.465, p = 0.039). As expected,
serum cystatin C level was negatively associated with esti-
mated GFR level (r = −0.892, p = 0.001) only in group 2 (Fig. 1).
In group 3, only a negative signiﬁcant correlation was present
between LDL and cystatin C (r = −0.72, p = 0.002). In group 4,
cystatin C had a positive correlation with duration of dia-
betes (r = 0.453, p = 0.045) and a negative correlation with MA
(r = −0.520, p = 0.019) (Fig. 2).
When all the patients which are taken to the study are
evaluated, statistically signiﬁcant relation in negative direc-
tion and in % 72.6 level is detected (r = −0.726, p = 0.001).
Signiﬁcant negative correlation is detected between GFR and
creatinine (r = −0.806, p = 0.001). Positive signiﬁcant correlation
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Table 1 – Laboratory parameters of the study groups.
Group 1 (n = 20) Group 2 (n = 21) Group 3 (n = 17) Group 4 (n = 20) p
Age, years 62.9 (5.8) 59.7 (6.9) 49.0 (8.0) 53.7 (8.3) 0.001
Duration of Diabetes Mellitus, months 116.4 (100.1) 127.4 (96.7) 96.0 (71.8) 78.0 (45.1) 0.243
BMI, kg/m2 29.6 (4.2) 32.0 (5.3) 32.2 (6.6) 31.6 (5.4) 0.430
Glucose, mg/dL 118.8 (26.6) 152.1 (62.7) 143.9 (42.6) 121.1 (32.7) 0.043
HbA1c, % 6.1 (0.7) 6.9 (1.2) 7.3 (1.1) 6.7 (1.3) 0.028
Creatinine, mg/dL 1.2 (0.2) 0.9 (0.3) 0.6 (0.1) 0.6 (0.1) 0.001
Albumin, g/dL 4.2 (0.3) 4.2 (0.2) 4.3 (0.3) 4.3 (0.3) 0.559
HDL-Cholesterol, mg/dL 41.2 (10.1) 38.4 (7.8) 39.8 (10.9) 40.5 (5.7) 0.774
LDL-Cholesterol, mg/dL 102.6 (35.5) 115.3 (34.3) 129.6 (30.3) 105.9 (29.6) 0.079
Triglyceride, mg/dL 148.3 (91.1) 174.8 (79.9) 175.9 (50.9) 184.6 (68.1) 0.074
Sedimentation rate, mm/hour 22.3 (14.8) 15.1 (10.8) 13.4 (5.2) 14.2 (8.0) 0.412
hsCRP, mg/dL 5.1 (4.5) 6.0 (7.7) 5.5 (5.5) 5.6 (5.2) 0.969
Body mass index (BMI), hemoglobin A1c (HbA1c), high density lipoprotein (HDL), low density lipoprotein (LDL), high sensitive c reactive protein
(hsCRP).
Mean (standard deviation).
Table 2 – Evaluation of micro and macro vascular complications according to groups.
Group 1 (n = 20) Group 2 (n = 21) Group 3 (n = 17) Group 4 (n = 20) p
Coronary Artery Disease 9 (45%) 10 (47.6%) 1 (5.9%) 2(10%) 0.003
Retinopathy 5 (25%) 7 (33.3%) 2 (11.8%) 4 (20%) 0.454
8%) 
.9%) Diabetic Foot 0 (%0) 1 (4.
Neuropathy 9 (45%) 9 (42
is detected between age, hypertension and CAD and cystatin
C levels (for age r = 0.534, p = 0.001; for hypertension r = 0.347,
p = 0.002; for CAD r = 0.382, p = 0.001, respectively).
When 60 ml/min/1.73 m2 is selected for GFR as the cut-off
value, it is observed that the cystatin C levels are signiﬁcantly
different between the patients who have eGFR values over
and below this cut-off point (GFR < 60 ml/min: 1548.6 ± 613.8;
GFR ≥ 60 ml/min mean: 816.8 ± 310.8; p = 0.001). ROC analysis
for cystatin C, in the cases where cystatin C is C ≥ 1064 mg/L,
catch-up sensitivity of GFR in <60 ml/m was calculated as 80%,
speciﬁcity as 86.21%; positive conjecture value as 66.67% and
negative conjecture value is calculated as 92.59% (Fig. 3). The
area under the curve in ROC analysis was found as 85.4% and
standard error was calculated as 6%.
DiscussionThe albumin excretion rate (AER) which is used in staging
of DN and GFR, is not sufﬁcient for explaining the disease
progress. While albumin excretion through urine is normal,
GFR can decrease without any increase in AER. By considering
Table 3 – Estimated GFR, cystatin C, serum and urine TGF-1, a
Group 1 (n = 20) Group 2 (n = 21) 
eGFR, mL/m/1.73 m2 54.7 (7.6) 78.2 (23.5) 
Cystatin C, mg/L 1.4 (0.6) 1.1 (0.4) 
sTGF-1, ng/mL 16.7 (6.9) 18.9 (3.0) 
uTGF-1, pg/mg cre 558.6 (23.0) 633.2 (100.6) 
MA, mg/24 h 18.0 (5.9) 89.8 (37.7) 
Estimated glomerular ﬁltration rate (eGFR), serum transforming growth fac
1), microalbuminuria (MA).
Mean (standard deviation).0 (%0) 0 (%0) 0.432
2 (11.8%) 5 (25%) 0.096
that DN may have normoalbuminuric stage,11 this situation is
reported in type 1 diabetic patients who show typical speciﬁ-
cations in favor of DN in renal biopsy.11 In our study, when
detecting the early stage diabetic nephropathy, cystatin C
levels are detected as higher in the groups which have nor-
moalbuminuric eGFR <60 ml/m/1.73 m2 and as independent
from eGFR serum and urine TGF-1 level is detected as higher
in microalbuminuria group.
In AER and GFR relation age is an important factor.
GFR is type 2 diabetics over 70 years old, is approximately
60 ml/m/1.73 m2. In our study, eGFR was the lowest and the
age was the oldest in normoalbuminuric group (average 62 ± 5
years).
Today, GFR is accepted as the best index reﬂecting kidney
function.13 GFR can be directly measured with the infusion of
the exogenous markers such as inulin or 51Cr-EDTA. However
these methods are not practical and not used in daily practice.
Therefore, for the sake of practicality, American Diabetes
Association (ADA) and National Kidney Foundation suggest
the formula of Cockcroft-Gault (CG) and Modiﬁcation of Diet
in Renal Disease four-variable (MDRD) equations to estimate
nd MA levels in study groups.
Group 3 (n = 17) Group 4 (n = 20) p
125.7 (6.9) 106.1 (29.8) 0.001
0.6 (0.1) 0.7 (0.1) 0.001
16.1 (6.1) 13.2 (6.4) 0.022
539.3 (204.3) 442.2 (214.3) 0.022
22.2 (8.9) 16.3 (5.1) 0.001
tor-beta 1 (sTGF-1), urine transforming growth factor-beta 1 (uTGF-
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dFR.14,15 Particularly MDRD equation is accepted as superior
han CG owing to not depend on body weight measurement.13
Serum creatinine concentration is an imperfect measure
f GFR. In our study, the creatinine level in the patient groups
hose GFR was <60 ml/m/1.73 m2, has not increased yet and
he patients were normoalbuminuric. Since serum creatinine
evel is affected by muscle mass and diet, it is not an ideal
arker for GFR calculation. Novel methods are needed for
arly and accurate detection of DN.
Cystatin C is an endogenic marker used for GFR determina-
ion because its serum level is dependent to almost whole of
GFR particularly it is seen more  valuable in normal and mild
ecreased eGFR.8
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Laterza et al.5 have attributed cystatin C to be an important
reagent in early stage kidney damage to its stabile produc-
tion, muscle mass, not being dependent to age and gender
or not showing reverse tendency to kidney secretion or blood
circulation.
In our study, the difference in cystatin C levels showed that
even in normoalbuminuria stage, the diabetic renal disease
can be identiﬁed.
In early diabetic kidney disease, there are contradictory
results related to the role of cystatin C. As pursuant to our
study, two studies show that cystatin C is not more  sensi-
tive than creatinine.16,17 Contrary to our results, in the study
where cystatin C based equations and creatinine based equa-
tions like Schwartz, MDRD and CG formulas are compared
and in a meta-analysis where 46 studies included, cystatin
C is considered superior than creatinine in determination
of decreased GFR.18,19 Although a negative weak relation is
detected in cystatin C and eGFR in our study, it was not statis-
tically signiﬁcant. We think that this situation might be due to
the limited number of cases in the patient group. In the study
where Mussap and colleagues have examined 52 type 2 dia-
betic patients,20 eGFR has decreased from 120 ml/m/1.73 m2 to
20 ml/m/1.73 m2 and cystatin C has increased more  than the
serum creatinine has. The association between Cystatin C and
eGFR was detected stronger than the serum creatinine.
In the study of Surendar et al. in Indians who have glu-
cose intolerance, it was determined that cystatin C levels have
increased as comparative with glucose intolerance and the
highest cystatin C levels were found in the group which had
microalbuminuria and retinopathy.21 In our study, no differ-
ence was detected in terms of retinopathy among the groups
and cystatin C levels were found highest in the normoalbu-
minuric group.
In the previous study, ROC analysis made for identifying
the diagnostic proﬁle of serum cystatin C in predicting eGFR
<60 ml/dk/1.73 m2 in the type 2 diabetic patients and as similar
to our study, cut-off value is detected as 1.06 mg/dl, the sen-
sitivity of serum cystatin C level is 81% and the speciﬁcity is
detected as.22 As pursuant to our study, serum cystatin C level
of the normoalbuminuric is detected as signiﬁcantly higher
than the patients with GFR of ≤60 ml/dk/1.73 m2. This makes
us think that cystatin C levels of serum and urine are related
with the subclinical failure and may be the kidney uptake
reagents which are measurable in the period earlier than the
onset of albuminuria. In the study of Yang and friends, serum
cystatin C level showed correlation with MA level.23
When we consider the relation between serum cystatin C
and serum creatinine levels and MDRD in whole study pop-
ulation we  determined that the predictive ability of serum
creatinine for GFR was higher. This result, which is discordant
with the majority of the literature, can be connected to the
insufﬁciency of the cases in patient groups, selecting the case
from the patients who have early period DN and formation
of 25% of the total patient population by microalbuminuric
patient group.
In the microalbuminuric patient group and in the patient
group with GFR <60 ml/m/1.73 m2 or >60 ml/m/1.73 m2, nega-
tive and signiﬁcant association was found. This patient group
was the sole patient group with MA. This group was made
up from older patients than normoalbuminuric and two other
 0 1 6;
r
1
1
1
1658  n e f r o l o g i a 2
patient groups with GFR >90 ml/m/1.73 m2. It is known that
the serum cystatin C level increases with advancing age. The
presence of signiﬁcant difference among the patient groups in
terms of age, can be seen as another factor which limits our
study.
In both studies, high serum cystatin C level is associated
with the previous coronary heart disease.24,25 As similar to
these studies, we  have found positive signiﬁcant correlation
between CAD and serum cystatin C in the whole patient
cohort.
One of the cytokines which is responsible for DN initiation
and progression is TGF-. It is proven that TGF- intervenes to
all pathological changes which depend on the diabetic kidney
disease.26 TGF- causes kidney cell hypertrophy and exces-
sive extracellular matrix production in interstitial ﬁbroblasts,
glomerular and tubular cells.
In experimental DM,  glomerular and tubule-interstitial
compartments, expresses TGF- or TGF- type II receptor.
Although the kidney of the non-diabetic subject removes TGF-
1 from the blood, kidney of a diabetic patient releases TGF-1
protein into the circulation. TGF-1 level which has increased
in urine is associated with adverse clinical outcomes.27 In 3
patient groups which do not have MA  in our study, we have
found the serum and urine TGF-1 levels were signiﬁcantly
higher in the groups with MA.
Increased kidney TGF-1 production in the diabetic
patients was examined and renal vein TGF-1 concentra-
tion was found positive in diabetic patients and negative in
non-diabetic patients.27 Urine TGF-1 level in the diabetic
patients increased fourfold than the non-diabetic patients and
as contrary to our study, increased urine TGF-1 excretion was
present in all diabetic patients irrespective of MA  status.
There are some limitations of our study that need to be
mentioned. The most important limitation of our study is
the estimation of GFR measurements. All estimates of GFR
based on serum creatinine will be affected from physiologic
and/or pathologic limitations28 and be far from ideal GFR. On
the other hand, recent studies showed the CKD-EPI creatinine
equation has similar GFR prediction in different patient pop-
ulation compared with the MDRD Study equation, even in the
earlier CKD stages.29,30 In addition, the CKD-EPI creatinine-
cystatin C equation is more  suitable compared with standard
reference for cystatin C and creatinine based equations.31
However, the cost effectiveness of the CKD-EPI creatinine-
cystatin C equation for clinical use should be considered. The
second important limitation is the sample size of the study
groups. But we  wanted to be sure about patients with type 2
diabetes mellitus without known overt diabetic nephropathy.
Larger new clinical trials are recommended to determine the
role of serum cystatin C, serum and urine TGF-1 level as an
early biomarker of diabetic nephropathy. The third, diabetic
foot ulcer with or without concomitant peripheral arterial dis-
ease is considered as two separate disease.32 In our study,
we  did not exam the patients whether they have peripheral
vascular disease.Conclusion
Although urinary albumin excretion is suggested for detection
of type 2 diabetic nephropathy, there is group of patients with
13  6(6):653–659
decreased eGFR but without increased urinary albumin excre-
tion, in which serum cystatin C level was indicated to be used
as an early biomarker of diabetic nephropathy. In addition,
despite that serum and urine TGF-1 levels were also signiﬁ-
cantly higher in patients with MA, only increased urine TGF-1
excretion was present in all diabetic patients irrespective of
MA status.
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